QUECTEL-WIRELESS
Quectel Wireless Solutions, a global IoT solutions provider, has made further additions to its comprehensive range of antennas for IoT devices and deployments. The latest launches include the YEMN016AA and YEMN017AA 5G 5-in-1 combination antennas, the YECN001J1A and YECT000WBA external 5G antennas and the YEGB000Q1A and YEGN000Q1A active GNSS L1 and L5 antennas.
“We are thrilled to expand our product line with antennas that offer superior performance and meet the unique needs of our IoT customers,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Quectel consistently enhances its diverse portfolio to precisely address the unique requirements of our clients' deployments and applications, offering unparalleled performance and adaptability, and these antennas add to that portfolio.”
The YEMN016AA is a 5G and global navigation satellite systems (GNSS) 5-in-1 antenna measuring 204.4mm x 86.7mm x 32mm. This ultra-wide-band 5G/4G antenna provides broad coverage from 600–6,000MHz whilst offering backward-compatibility to support 3G and 2G networks as well as LTE Cat-M and narrowband IoT (NB-IoT). The antenna is available with connection via five cable lengths from 300–5,000 mm, terminated with SMA connectors. This low profile, screw mount omnidirectional antenna, ideal for applications where the antenna is required to be discrete, is easy to install with maximum durability assured thanks to its IP69K PC KIBILAC® ASA enclosure. It is compatible with Quectel's RM520x Series modules.
The Quectel YEMN017AA is a 5G screw mount 5-in-1 antenna puck optimized for 5G and 4G networks. With a diameter of 103.5mm and height of 42.5mm, the antenna can integrate a variety of antennas, such as 5G, 4G, GNSS and Wi-Fi antennas. Available with multiple mounting options including screw, pole, wall, magnetic, adhesive and others, the antenna box supports multiple connector types and cable lengths and is designed to offer a more flexible and reliable high-performance antenna for outdoor applications.
Quectel has also added the YECN001J1A and YECT000WBA external 5G antennas to its portfolio. Both antennas cover the 5G NR Sub-6 GHz frequency bands and are compatible with 4G, 3G, 2G and LPWA bands. Featuring high efficiency and gain, both offer an ideal omni-directional antenna solution to ensure high-speed data transmission. Ideal for a diversity of wireless communication devices such as routers, outdoor equipment and real-time monitoring equipment, the antennas feature a diameter of 40.6mm and height of 104mm. The antennas are both RoHS and REACH compliant and Quectel offers flexible installation with custom cable length and connector options.
For users prioritizing GNSS, Quectel has introduced the YEGB000Q1A and YEGN000Q1A active GNSS L1 and L5 antennas. Operating in the 1164-1189MHz and 1559-1606MHz frequency bands these antennas measure 62mm x 56mm x 23mm. The antennas support different installation or connection methods such as screw mount, adhesive mount, magnetic mount, internal cable, and external SMA. Customized connector types and cable lengths are provided according to requirements.
In common with all Quectel antennas, Quectel provides comprehensive antenna design support such as simulation, testing and manufacturing for custom antenna solutions to meet customers’ specific application needs. In addition, Quectel antennas can be pre-integrated with Quectel’s vast range of modules.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327795741/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brisbane Airport embraces advanced analytics from Cirium Sky Warehouse17.3.2025 23:00:00 CET | Press release
Queensland’s major airport pioneers data consolidation in the cloud to drive operational efficiency Brisbane Airport (BNE), which serves as the major gateway to Queensland, has partnered with aviation analytics firm, Cirium, to become one of the first airports to integrate Cirium Sky Warehouse, a data-driven cloud platform, into its modernisation efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317052819/en/ Brisbane Airport Cirium’s advanced data and analytics will be seamlessly integrated with Brisbane Airport’s business systems. This integration will support enhanced capacity planning, resource allocation, and operations analysis. Jeremy Bowen, Cirium CEO, commented: "We are delighted to support Brisbane Airport’s transformative investment to revolutionise its passenger experience and meet future travel demand. “Integrating Cirium data and analytics through the Cirium Sky Warehouse will help the airport to conso
Trump-Inspired World Liberty Financial Closes $550 Million Across Token Sales17.3.2025 20:37:00 CET | Press release
WLFI completes second set of WLFI governance token sales World Liberty Financial, Inc. (“WLFI”), the developer of a pioneering DeFi protocol and governance platform inspired by Donald J. Trump, has made history with the completion of the second set of its token sales, totaling $550 million in gross proceeds in concurrent U.S. and non-U.S. token offerings. After launching on October 15, 2024, WLFI has successfully concluded two sets of token sales in concurrent U.S. and non-U.S. offerings. In the first set, $300 million USD of WLFI tokens were sold between the offerings, and in the second set, $250 million USD of WLFI tokens were sold between the offerings. Between all the offerings, $550 million USD in WLFI tokens have been sold. More than 85,000 total participants in the token sales underwent Know Your Customer (KYC) process to determine participation eligibility. "This milestone proves that those who truly understand crypto and finance recognize what we’re building — and that WLFI is
RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product17.3.2025 20:28:00 CET | Press release
The Company Received Approval in Multiple European Countries to Initiate this Key Study Necessary for Commercial Product Approval RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306978603/en/ RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege. “The results from th
Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 203017.3.2025 19:00:00 CET | Press release
Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects under the French government’s France 2030 initiative. Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance. Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases. Egle Therapeutics has developed a propri
The World Celebrates Ireland This St Patrick’s Day17.3.2025 16:19:00 CET | Press release
People around the world revelled in all things Irish on 17th March – the annual global celebration of Irish culture, arts and heritage known as St Patrick’s Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317647496/en/ In Dublin, around half a million people lined the streets of the capital for the St Patrick’s Festival parade, which this year has the theme of ‘Adventures’ – or ‘Eachtraí’ in Irish – representing the legendary adventurous Irish spirit, loved the world over. St Patrick's Day is marked all over the world by the 70 million who claim links to Ireland. Celebrating Ireland’s national colour, the defining natural green lands, the Global Greenings returned for St Patrick’s Day, with iconic international landmarks lighting up in green including Niagara Falls, the Leaning Tower of Pisa, the Empire State Building, the Sky Tower in Auckland, the Royal Liver Building in Liverpool, the Sacré-Cœur in Paris, as well a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom